Adjuvant Therapy for Resected Non–Small-Cell Lung Cancer with Lymphovascular Invasion  by Rami-Porta, Ramón
e9Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 8, Number 1, January 2013 Letters to the Editor
and adjuvant therapy in stage IA non–
small-cell lung cancer (NSCLC) 
patients with complete resection. 
Their main conclusion is that the pres-
ence of LVI is significantly associated 
with an increased risk of develop-
ing distant metastases (DM) on uni-
variate and multivariate analysis and 
also of local recurrence on univariate 
analysis. Consequently, they believe 
that adjuvant chemotherapy should be 
considered for these patients because 
DM and local recurrence were associ-
ated with worsening overall survival. 
They criticize the current National 
Comprehensive Cancer Network 
guidelines as somewhat ambiguous in 
this regard, stating that the presence 
of LVI is considered high risk, even 
though the influence of LVI on the 
recommended adjuvant treatment after 
complete resection remains unclear. 
Such ambiguity is clearly referred to 
in the data published by Ettinger et al.2 
The conclusions of Higgins et al.1 are 
shared with additional published data 
on the appropriateness of the indica-
tion for adjuvant chemotherapy for 
these high-risk patients with NSCLC 
stage IA. Tsuchiya et al.3 believe there 
must be a more appropriate valuation 
of the role of LVI as a new target for 
adjuvant chemotherapy in patients 
with NSCLC stage IA. On the basis of 
a meta-analysis of six randomized con-
trolled trials, Hamada et al.4 observed 
a benefit of adjuvant chemotherapy 
in patients with complete resection 
of NSCLC stage IA T1b (diameter > 
2 cm).
Bodendorf et al.5 reported that 
LVI in NSCLC stage IA has strong 
prognostic significance, implying the 
necessity of considering how this will 
reflect on decisions regarding adjuvant 
chemotherapy. In a study of broncho-
genic carcinoma with specific reference 
to the 7th Edition of the TNM classifi-
cation, Igai et al.6 reported that adjuvant 
chemotherapy is indicated for NSCLC 
stage IA p-T1 aN0M0 patients with LVI 
and complete resection. Funai et al.7 are 
convinced that adjuvant chemotherapy 
after complete resection in patients with 
adenocarcinoma stage IA p-T1 aN0M0 
is an unavoidable treatment in the event 
of LVI.
At the 2nd European Lung Cancer 
Conference (Geneva 2010), Ruffini et al.8 
affirmed that LVI is still underestimated, 
given the prognostic outlook and role of 
adjuvant chemotherapy in patients with 
complete resection of stage IA NSCLC.
In their extensive study of the 
relevant prognostic value of LVI in T1a 
and T1b patients, Naito et al.9 strongly 
suggest updating the guidelines con-
cerning the indications for adjuvant 
chemotherapy in NSCLC stage IA radi-
cal resection patients.
In conclusion, current data 
increasingly demonstrate that revi-
sion of the criteria excluding adjuvant 
chemotherapy for patients with radical 
resection for NSCLC stage IA with LVI 
is mandatory. In the new scenario in 
the 2009 TNM classification, the terms 
not indicated and contraindicated must 
be reconsidered in an updated amend-
ment. A risk-guided strategy focused 
on: (a) overall survival, (b) disease-
free survival, and (c) the incidence of 
local recurrence and DM should be 
developed for lung carcinoma patients 
at high risk of these unfavorable devel-
opments. Moreover, referring to spe-
cific patient subgroups guarantees the 
proper respect for the trend to pursue 
personalized treatment making use of 
biomolecular and pathomorphological 
parameters.
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In Response:
The Letter to the Editor by Salvati1 
commenting on the original article by 
Higgins et al.2 and elaborating on the 
adverse prognosis of lymphovascular 
invasion (LVI) in resected non–small-
cell lung cancer raises an important 
issue for current clinical practice: 
the suitability to administer adjuvant 
therapy to patients whose resected 
tumors have LVI, when there are no 
clear guidelines on the topic. Higgins 
et al.2 showed that LVI is associated 
with higher risk of distant metastases 
and shorter long-term survival in a pop-
ulation of patients with predominantly 
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stage IA and IB tumors; and Salvati1 
reviewed the available literature on the 
same topic, showing that there is a gen-
eral agreement on the adverse progno-
sis of LVI in the reported series. Why, 
then, the administration of adjuvant 
chemotherapy is not clearly indicated in 
clinical guidelines?
LVI is not the only pathologic 
feature that is associated with worse 
prognosis. Perineural invasion, visceral 
pleura invasion, and positive pleural 
lavage cytology are descriptors of the 
tumor (T), node (N), and metastasis 
(M) classification that, together with 
LVI, have not attracted much attention. 
Visceral pleura invasion is the only one 
that upstages a tumor to T2a, if its size 
is 3 cm or less, and there are no other 
features that determine a higher T. 
Perineural invasion (Pn) and LVI (L and 
V) are optional descriptors, whereas 
pleural lavage cytology (cy) has specific 
codes for positive (cy+) and negative 
(cy−) results; it does not alter the T or 
the M components of the tumor classi-
fication, but the resection is considered 
microscopically incomplete if pleural 
lavage cytology is positive (R1cy+).3
In the ideal world, therapeutic 
recommendations should derive from 
properly designed randomized clinical 
trials (RCTs). The results from RCTs 
on therapeutic options have the highest 
level of evidence, and these are the ones 
that should be recommended in clinical 
guidelines on therapy. When there are no 
RCTs, as is the case with LVI, perineural 
invasion, visceral pleural invasion, and 
positive pleural lavage cytology, the mul-
tidisciplinary team in charge will have to 
assess the best therapeutic option for each 
patient. In their comment on the rationale 
for adjuvant chemotherapy in stage I 
non–small-cell lung cancer, Horn et al.4  
propose an algorithm that may help the 
multidisciplinary team make therapeutic 
decisions. In this algorithm, adjuvant che-
motherapy is recommended in patients 
who have had an uneventful postoperative 
course, have a good performance status, 
and whose tumors are larger than 3 cm 
or have LVI, visceral pleural invasion, 
cavitation, or had a suboptimal lymph 
node sampling or dissection. The patients 
must understand that their tumors, even 
small in size, have a high potential for 
recurrence, and must accept the 
limitations of the recommendation of 
adjuvant treatment. Given these cir-
cumstances, the multidisciplinary team 
should not be reluctant to indicate adju-
vant chemotherapy for these tumors with 
pathological features of invasiveness.
In the prospective phase of the 
International Association for the Study 
of Lung Cancer Staging Project, these 
pathological features are registered. 
They not only have therapeutic but also 
staging implications. Provided there is 
consistence in the findings across the 
world, they may modify either the T 
or the M components of the classifica-
tion, as visceral pleura invasion does. 
It is only by the accumulation of large 
databases and the conduction of RCTs 
with stratification by these pathologic 
features that we will be able to avoid the 
likelies and the perhapses in our pres-
ent statements and answer most of the 
questions that persist even today.5
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